Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN.
Although autologous tandem hematopoietic SCT has improved the prognosis of patients with advanced high-risk neuroblastoma, the results remain unsatisfactory. In an attempt to induce the graft-versus-tumor effect, we performed autologous PBSCT followed by allogeneic cord blood transplantation in three consecutive advanced neuroblastoma cases with marked BM infiltration and high MYCN amplification. Severe acute complications did not occur in any patient and they have maintained disease-free survival for 37-60 months. This strategy appears to be feasible and effective for the treatment of extremely high-risk neuroblastoma cases.
Goi
K
K
Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. kgoi@yamanashi.ac.jp
Inukai
T
T
Honna
H
H
Akahane
K
K
Hirose
K
K
Kuroda
I
I
Hasuda
N
N
Koshizuka
K
K
Takano
K
K
Sugita
K
K
D001853:Bone Marrow / Q000473:pathology; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007223:Infant; D008297:Male; D000071447:N-Myc Proto-Oncogene Protein; D009361:Neoplasm Invasiveness; D009447:Neuroblastoma / Q000628:therapy*; D009687:Nuclear Proteins / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*
C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins